What guidance did Rani Therapeutics's management provide for the next earnings period?

What were the key takeaways from Rani Therapeutics’s earnings call?

What is Rani Therapeutics's gross profit margin?

What is the revenue and EPS growth rate for Rani Therapeutics year over year?

What were the key takeaways from Rani Therapeutics's earnings call?

What factors drove the changes in Rani Therapeutics's revenue and profit?

What is the market's earnings forecast for Rani Therapeutics next quarter?

What is Rani Therapeutics's latest dividend and current dividend yield?

- **$1.1B Chugai Collaboration**: Validates RaniPill platform scalability with potential expansion to 5+ drug targets.
- **Phase I Trial Initiated**: RT-114 enters clinic with focus on tolerability to differentiate in obesity market.
- **Strong Cash Position**: $49.7M cash runway into 2027, enabling strategic growth without dilution.
- **Cost Efficiency**: 25% YoY R&D expense reduction supports sustainable development.

**【CEO Summary Section】**
- **Strategic Partnerships**: Announced a collaboration with Chugai Pharmaceuticals valued at up to $1.1 billion, including an option for up to 5 additional drug targets, highlighting the scalability of the RaniPill platform.
- **Financial Strength**: Completed a $60.3 million private placement, extending cash runway into Q4 2027, and repaid all debt obligations.
- **Pipeline Progress**: Initiated Phase I trial for RT-114 (oral GLP-1/GLP-2 receptor agonist) in December 2025, with preclinical data showing comparable bioavailability and weight loss to subcutaneous delivery. RT-116 (oral semaglutide) also demonstrated comparable efficacy and tolerability.
- **Focus on Tolerability**: Emphasized the importance of minimizing adverse effects to improve patient adherence, differentiating from competitors in the obesity market.

**【CFO Financial Commentary】**
- **Cash Position**: $49.7 million as of Q4 2025, up from $27.6 million, driven by private placement and Chugai upfront payment.
- **Revenue**: Contract revenue of $1.6 million for FY 2025, primarily from Chugai agreement; R&D expenses decreased 25% YoY to $20.2 million due to cost containment.
- **Net Loss**: $41 million for FY 2025, down 28% YoY, with reduced stock-based compensation.

**【Q&A Highlights】**
- **RT-114 Trial Expectations**: Phase Ib study will report weight loss data alongside bioavailability, aiming to replicate ProGen's subcutaneous PG-102 results with improved tolerability.
- **Partnership Strategy**: Successful Phase I data could accelerate discussions with Chugai on additional targets and attract new partners, leveraging RaniPill's broad applicability across therapeutic areas.

Rani Therapeutics Holdings, Inc.(RANI)-20260327-2025 Q4 Earnings call transcript

- **Breakthrough oral biologics platform:** RaniPill achieves 107% bioavailability for semaglutide, comparable to subcutaneous injection, with potential for weekly dosing in obesity.
- **Pipeline focus:** RT-114 (GLP-1/GLP-2) set to enter Phase 1 in mid-2025; preclinical data shows 6.7% weight loss in canines with better tolerability than subcutaneous delivery.
- **Financial resilience:** $27.6M cash runway into Q3 2025; cost-cutting reduces R&D expenses by 12.9% YoY.
- **Strategic differentiation:** Oral delivery of novel GLP-1/GLP-2 aims to preserve lean body mass, addressing FDA guidance on body composition in obesity treatments.
- **Global expansion potential:** Semaglutide program could target non-US markets post-patent expiry with accelerated timelines.


**【CEO Summary Section】**
- Rani Therapeutics' RaniPill technology enables oral delivery of biologics with bioavailability comparable to subcutaneous injection, targeting high-value markets like obesity and immunology.
- Key pipeline advancements include RT-114 (GLP-1/GLP-2 dual agonist) and RT-116 (semaglutide), with preclinical data showing 107% relative bioavailability for semaglutide and comparable weight loss to subcutaneous delivery.
- RT-114 is expected to enter Phase 1 clinical trials in mid-2025, focusing on obese patients with BMI >30. The program aims to address tolerability challenges of first-generation incretin therapies.
- Strategic partnership with ProGen Co. Limited for RT-114 highlights potential for a differentiated product with weekly dosing and lean body mass preservation.

**【CFO Financial Commentary】**
- Cash, cash equivalents, and marketable securities as of December 31, 2024: $27.6 million (sufficient for operations into Q3 2025).
- Contract revenue for Q4/FY2024: $1 million (testing partner drugs via RaniPill).
- R&D expenses: $6.8M (Q4) / $26.7M (FY2024), down 12.9% YoY due to cost containment.
- G&A expenses: $5.5M (Q4) / $23.9M (FY2024), down 2.5% YoY.
- Net loss for FY2024: $56.6 million (includes $3.7M impairment loss on manufacturing assets).

**【Q&A Key Highlights】**
- **RT-116 (semaglutide):** No immediate clinical plans; focus on RT-114 due to capital constraints. Potential for accelerated development in non-US markets post-patent expiry.
- **COGS:** Targeting cost parity with injectables via manufacturing automation and scale.
- **Clinical trial flexibility:** Oral formulation allows dose splitting to manage tolerability (e.g., nausea/vomiting).
- **BD activity:** Interest from pharma in obesity, immunology, and rare disease; collaboration with large pharma on RaniPill platform.
- **ProGen's PG-102:** Phase 1 data shows 4.8% weight loss at 80mg, rapid titration with no discontinuations; RaniPill version (RT-114) aims to replicate results with weekly dosing.
- **Regulatory strategy:** Leverage ProGen's subcutaneous program timeline for RT-114 regulatory filings.


Actual	-0.12	-0.16	-0.27	-0.29	-0.31	-0.33	-0.35	-0.33	-0.37	-0.36	-0.27	-0.29	-0.26	-0.24	-0.27	-0.22	-0.18	-0.07
Forecast	-0.176	-0.18	-0.495	-0.66	-0.516	-0.5249	-0.401	-0.467	-0.4244	-0.426	-0.38	-0.278	-0.3352	-0.29	-0.2688	-0.28	-0.285	-0.0475
Surprise	+31.82%	+11.11%	+45.45%	+56.06%	+39.92%	+37.13%	+12.72%	+29.34%	+12.82%	+15.49%	+28.95%	-4.32%	+22.43%	+17.24%	-0.45%	+21.43%	+36.84%	-47.37%

Actual	1.96M	0	0	0	0	0	0	0	0	0	0	0	0	0	1.03M	172.00K	0	1.46M
Forecast	490.00K	630.00K	162.50K	325.00K	130.00K	130.00K	108.33K	0	0	0	0	0	0	0	0	0	0	5.00M
Surprise	+300.20%	-100.00%	-100.00%	-100.00%	-100.00%	-100.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-70.78%

RANI

RANI fundamentals

RANI Q4 2025 Earnings

Earnings Call

You can ask Aime

RANI

RANI fundamentals

RANI Q4 2025 Earnings

Earnings Call

RANI Earnings Call Summary for Q4/20254:30 PM on Mar 26, 2026

RANI Earnings Call Summary for Q2/2025 Apr 1, 2026

RANI Earnings Call Summary for Q1/20259:30 AM on May 15, 2025

RANI Earnings Call Summary for Q4/20244:30 PM on Mar 31, 2025

RANI Earnings Call Summary for Q3/2024 Apr 1, 2026

You can ask Aime